Bio/Pharma News

AI Biotech Secures Funding to Speed Up Stem Cell Therapy Development

January 16, 2024

CellVoyant has raised £7.6 million in seed funding to speed up the development of novel cell therapies.

Boehringer Ingelheim Expands Facility in Greece for Production of New Therapeutics

January 15, 2024

Boehringer Ingelheim is investing €120 million (US$131 million) into its Koropi, Greece site to expand production for new therapeutics.

GSK to Acquire Aiolos Bio, Expands Respiratory Portfolio

January 09, 2024

In a deal worth up to $1.4 billion, GSK aims to acquire Aiolos Bio and gain an expanded pipeline of biologic-based respiratory therapeutic candidates.

Leiters Health Recalls Vancomycin IV Bags, Phenylephrine IV Bags, and Fentanyl IV Bags

January 09, 2024

The potential for superpotent drug initiated the voluntary recall.

DoD Grants Additional Funds to MediWound for Advancement of Non-Surgical Treatment for Field Care Burns

January 05, 2024

MediWound has been granted an additional $6.7 million by the DoD to advance NexoBrid as a non-surgical field care solution for the US military.

Boehringer Ingelheim and Ribo Partner on RNA-based Liver Disease Therapeutics

January 05, 2024

Under the collaboration, Boehringer Ingelheim and Ribo will develop RNA-based therapeutics to treat NASH/MASH.

Roche to Acquire Point-of-Care Technology from LumiraDx in $350 Million Deal

January 04, 2024

Roche will acquire select parts of the LumiraDx group related to that company’s point-of-care technology, which integrates multiple tests on a single instrument.

AstraZeneca Poised to Acquire Cell Therapy Developer, Gracell, in Deal Valued at $1.2 Billion

January 04, 2024

AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.

QurAlis Opens European Headquarters in The Netherlands

January 04, 2024

The new Europe headquarters will be the hub for the company’s European operations, including production of product.

AstraZeneca to Acquire Icosavax in Deal Valued at Approximately $1.1 Billion

January 02, 2024

With the acquisition, AstraZeneca will gain a potential RSV and hMPV combination vaccine.